Red blood cells are disks curved inwards on both sides ... The clots change oxygen and acidity locally, causing more sickling. Accumulation of clots causes some of the most severe symptoms ...

Researchers have developed a new model to track inflammation-driven blood clots that can cause complications in sickle cell ...

In December 2023, the US Food and Drug Administration (FDA) approved Casgevy and Lyfgenia, cell-based therapies that modify a person's genes and prevent the "sickling" of red blood cells.

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

A first in human proof of concept phase I clinical study of VAS-101 (Vasceptor®; topical curcumin gel) in sickle cell disease (SCD) is underway. The study is being conducted by the Foundation for ...

the molecular basis of sickling and destruction of red blood cells in SCD. The product has been launched in 35 countries around the world, including the US and Europe, and sales rose by 73% to ...

A history of sickle cell disease and pharmaceuticals ... cellular and membrane abnormalities of red blood cells ultimately converging in erythrocyte sickling, aggregation and chronic haemolysis.

Specifically, heterozygous (Ss) individuals express both normal and sickle hemoglobin, so they have a mixture of normal and sickle red blood ... cell allele (ss), however, may have sickling ...

Oxbryta was the first medicine approved in Europe that directly prevents sickle haemoglobin (HbS) polymerisation, the molecular basis of the sickling and destruction of red blood cells in SCD that ...